



13 OTTOBRE

LA GIORNATA NAZIONALE  
del tumore mammario metastatico

*Linee guida europee*


*Dr.ssa Simona Di Lascio*

*SCDU Oncologia Azienda Ospedaliera*

*Universitaria "Maggiore della Carità" Novara*

# Disclosures

- Advisory board : Lilly, Astrazeneca, Roche, Pfizer, Novartis
- Travel grant: Astrazeneca, Roche, Pfizer, Lilly



Escat IA: prospective trials

Escat IIA: retrospective trials


Escat IC: basket trials

Brain imaging should not be routinely carried out in all asymptomatic patients; maybe only in patients with asymptomatic HER2-positive BC or TNBC have higher rates of brain metastases (BMs) at initial MBC diagnosis..

The imaging modality chosen at baseline should be applied for disease monitoring to ensure comparability [III, B].

-ET alone in the first-line setting reserved for the small group of patients with comorbidities or a PS that precludes the use of CDK4/6i combinations.  
 -OFS in addition to all endocrine-based therapies. In pre and perimenopausal pts

Somatic mutation testing (tissue or liquid)  
 Germline BRCA1/2 testing + PALB2



-If capecitabine is used, test DPD, before starting treatment.

The DESTINY-Breast04 phase III :  
 trastuzumab deruxtecan vs physician's choice of ChT, after one or two previous lines of ChT.


OlympiAD, EMBRACA: PARPi

Phase III EMERALD : elacestrant vs ET in patients with ER-positive MBC previously treated with other ET.


Phase III BOLERO-2 trial, everolimus-exemestane vs exemestane significantly improved median PFS (7.8 versus 3.2 months) in patients who had progressed on AI


In the PIK3CA-mutant cohort of the SOLAR-1 phase III trial, alpelisib provided a PFS benefit of 11.0 versus 5.7 months


Phase III TROPiCS-02 :  
 After at least two systemic ChT regimens.




2nd-line treatment or progressing during neoadjuvant or adjuvant treatment (d)











*Surgery of the primary tumour may be considered for patients with bone-only metastasis, HR-positive tumours, HER2-negative tumours, patients <55 years, patients with OMD and those with a good response to initial systemic therapy [II, B].*

*Local ablative therapy to all metastatic lesions may be offered on an individual basis after discussion in a multidisciplinary setting [II, C]; however, it is unknown if this leads to improved OS.*

A vibrant, long-exposure photograph of a waterfall in a dense tropical forest. The water flows from the top center, creating a soft, ethereal veil as it descends. It then cascades over several large, dark rocks that are heavily covered in bright green moss. The foreground is dominated by these mossy boulders, some of which are partially submerged in the water. The background is filled with thick, green foliage, with sunlight filtering through the leaves, creating a dappled light effect. The overall atmosphere is serene and natural.

Grazie per l'attenzione